BridgeBio Pharma Inc
(FRA:2CL)
€
73.01
+1.57 (+2.2%)
Market Cap: 14.38 Bil
Enterprise Value: 15.73 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 70/100 
Q2 2026 BridgeBio Pharma Inc Earnings Call Transcript
Aug 10, 2026 / 08:30PM GMT
Release Date Price:
€73.01
(+2.20%)
Key Points
Positve
- Attruby continues to show strong commercial momentum, with Q2 2026 net product revenue of $222.4 million, a $35 million+ sequential increase, and the brand being the fastest-growing in the ATTR-CM space at 23%.
- New data from the Circulation: Heart Failure publication demonstrates Attruby's first-ever early and sustained direct kidney protective effects in ATTR-CM, including improved eGFR slope and reduced albuminuria, which could differentiate it from competitors.
- All three late-stage pipeline programs (BBP-418 for LGMD2I, encaleret for ADH1, and infigratinib for achondroplasia) have had their NDAs accepted by the FDA, with BBP-418 and encaleret receiving priority review and no advisory committee meetings planned.
- The failure of CARDIO-TTRansform, which studied eplontersen in combination with stabilizers, reinforces the case for stabilizer-first therapy, potentially benefiting Attruby's market position as the only near-complete stabilizer.
- The company closed a $1 billion preferred equity financing on July 1, 2026, bringing cash to approximately $1.7 billion, providing a strong runway to fund three upcoming launches and ongoing operations.
- Encaleret's potential is expanding beyond ADH1, with the RECLAIM-HP phase III trial in chronic hypoparathyroidism now screening, targeting a 200,000-patient market in the US and EU, which could be a blockbuster opportunity.
- Infigratinib's phase III PROPEL 3 results, published in NEJM, show the first-ever placebo-controlled arm span benefit in achondroplasia, and the oral dosing advantage could expand the market, with peak share potential above 65%.
- The company's financial position is improving, with operating loss narrowing by 20% year-over-year, and management expects to reach breakeven profitability by 2027.
- Real-world evidence, including an independent propensity score-matched analysis, shows Attruby associated with a 37% reduction in composite cardiovascular events and 34% reduction in hospitalizations versus tafamidis, with no outcome favoring the competitor.
- The company's commercial readiness for upcoming launches is ahead of schedule, with field teams hired and trained, and payer engagement underway for BBP-418, encaleret, and infigratinib.
Negative
- The CARDIO-TTRansform trial failure is a setback for the ATTR-CM community, and while it may benefit stabilizers, it also highlights the uncertainty in the competitive landscape, with potential for knockdown therapies to still compete in the future.
- Attruby's second-line or switch segment is settling into a lower, normalized steady state, with the forced Vyndaqel switching pool largely worked through, which could limit near-term growth from that segment.
- The company faces intense competition in the first-line ATTR-CM market, with Pfizer's tafamidis and other players, and management acknowledges the need to keep earning share quarter by quarter.
- Operating expenses increased significantly, up $94.5 million year-over-year, driven by investments in Attruby and launch preparations, which could pressure margins in the near term.
- The company's guidance for Attruby to reach blockbuster status in 2026 is based on worldwide sales including partner-recorded Beyonttra, not just US net product revenue, which may not meet investor expectations for US-only growth.
- There is uncertainty regarding the impact of the kidney protection data on prescribing behavior, with management noting it will take six to nine months to see commercial fruit, indicating a lag in realizing benefits.
- The company has not updated its peak share assumptions for Attruby following CARDIO-TTRansform, and management is waiting for more data from ESC and market research, leaving investors without clear guidance on upside.
- Infigratinib enters a market with established competitors (BioMarin's VOXZOGO and Ascendis's UVOOWL), and while the oral advantage is a differentiator, the market may be sticky, as evidenced by BioMarin's claim of only 10% switching from VOXZOGO.
- The company's reliance on real-world evidence and independent analyses, while growing, may not be sufficient to sway all physicians and payers, especially as tafamidis approaches generic entry in 2031, which could alter market dynamics.
- The company's financial runway, while strong, is dependent on successful execution of multiple launches and continued Attruby growth, and any delays or setbacks could strain cash resources.
Operator;Chinmay Shukla
Good afternoon. I will be your conference operator today. (Operator Instructions) Before we begin, I would like to remind everyone that todayâs call may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to statements about BridgeBioâs future operating and financial performance, business plans and prospects, and strategy.
These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements.
For a discussion of these risks and uncertainties, please refer to the disclosure in todayâs earnings release and BridgeBioâs periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law. With that completed, BridgeBio, you may begin your conference.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers